AZN Latest Headlines

Citi Keeps Their Buy Rating on AstraZeneca (AZN)

at www.tipranks.com (Tue, 18-Aug 4:05 AM)

AstraZeneca's Enhertu, Tagrisso deliver positive results in lung cancer trials

at seekingalpha.com (Mon, 17-Aug 10:25 AM)

AstraZeneca (AZN) Gets a Buy from J.P. Morgan

at www.tipranks.com (Mon, 17-Aug 7:55 AM)

AstraZeneca: Volrustomig Setback Offset by Oncology Pipeline Strength; Buy Rating and 16,500 GBp Price Target Maintained

at www.tipranks.com (Mon, 17-Aug 5:05 AM)

AstraZeneca’s Enhertu tops standard care in first-line HER2-mutant lung cancer trial

at www.tipranks.com (Mon, 17-Aug 2:32 AM)

AstraZeneca halts eVOLVE-Lung02 trial of volrustomig combo

at seekingalpha.com (Mon, 17-Aug 2:24 AM)

AstraZeneca Halts Key Lung Cancer Trial of Volrustomig After Missed Efficacy Goals

at www.tipranks.com (Mon, 17-Aug 2:19 AM)

AstraZeneca’s Tagrisso–Orpathys Combo Delivers Phase III Survival Gains in MET-Driven Lung Cancer

at www.tipranks.com (Mon, 17-Aug 2:08 AM)

AstraZeneca’s STEP Asthma Trial Completion: What It Could Mean for AZN Investors

at www.tipranks.com (Thu, 13-Aug 12:30 PM)

AstraZeneca Delivers 6% H1 Revenue Growth and Expands Pipeline with Major Regulatory Wins

Market Chameleon (Mon, 27-Jul 7:09 AM)

AstraZeneca and Abbisko Partner on First-in-Class Oral PD-L1 Therapy to Address Unmet Needs in EGFR-Mutated NSCLC

Market Chameleon (Thu, 2-Jul 7:29 AM)

FDA Approval of BAXFENDY Sets New Benchmark in Hypertension Treatment—AstraZeneca’s Latest Win Offers Hope for 23 Million US Patients

Market Chameleon (Mon, 18-May 9:21 AM)